Chemical Compound

Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1); Cabozantinib S-malate; Cabozantinib s-malate; Cometriq; XL 184; Cabozantinib L-malate salt; Cabozantinib (S)-malate

CAS Registry Number 1140909-48-3
Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1); Cabozantinib S-malate; Cabozantinib s-malate; Cometriq; XL 184; Cabozantinib L-malate salt; Cabozantinib (S)-malate 结构式
Primary record

Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1); Cabozantinib S-malate; Cabozantinib s-malate; Cometriq; XL 184; Cabozantinib L-malate salt; Cabozantinib (S)-malate

库存
7,558 克
纯度
99.6 %
CAS
1140909-48-3

化合物标识与属性

CAS
1140909-48-3
PubChem CID
25102846
SMILES
COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C([C@@H](C(=O)O)O)C(=O)O
Canonical SMILES
COc1cc2nccc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)c2cc1OC.O=C(O)C[C@H](O)C(=O)O

名称与同义词

  • Cabozantinib S-malate
  • Cabozantinib malate
  • cabozantinib (S)-malate
  • Cabometyx
  • 1140909-48-3
  • Cometriq
  • Cabozantinib malate (XL184)
  • Cabozantinib (S-malate)
  • cabozantinib L-malate
  • Cabometyx (TN)
  • Cometriq (TN)
  • RESNIBEN
  • XL184
  • Cabozantinib L-Malate Salt
  • XL-184 malate
  • Cabozantinib S-malate?
  • Cabozantinib s-malate [USAN]
  • DR7ST46X58
  • UNII-DR7ST46X58
  • RefChem:1080604
  • XL 184
  • XL-184
  • Cabozantinib malate (JAN)
  • Cabozantinib S-Malate salt
  • MFCD20923480
  • XL184(Cabozantinib malate)
  • CHEBI:72319
  • MLS006010951
  • C32H30FN3O10
  • Cabozantinib s-malate (USAN)
  • DTXSID60915949
  • BMS907351
  • orb1307421
  • BMS 907351
  • CHEMBL2103868
  • SCHEMBL29350740
  • SCHEMBL29881226
  • CABOZANTINIB MALATE [JAN]
  • HFCFMRYTXDINDK-WNQIDUERSA-N
  • DTXCID501510465
  • GLXC-10543
  • BMS-907351
  • C28H24FN3O5.C4H6O5
  • EX-A2819
  • KS-00000LA2
  • 2296AH
  • EBC-17171
  • s4001
  • 1140909-48-3 (malate)
  • 1140909-48-3 (malate salt)
  • AKOS025401945
  • CABOZANTINIB S-MALATE [WHO-DD]
  • CCG-270301
  • CS-0201
  • FC64967
  • AC-27471
  • AS-75255
  • HY-12044
  • SC-91041
  • SMR004702755
  • SY105860
  • 9-(4-chlorophenyl)sulfonylnon-6-en-2-one
  • CABOZANTINIB S-MALATE [ORANGE BOOK]
  • Cyclobutanol, 2-(phenylsulfonyl)-, trans-
  • (2,6-diphenylphenyl) 2-methylprop-2-enoate
  • B1401
  • SW218093-2
  • C10465
  • D10095
  • W-5841
  • Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
  • XL184 (S-malate);BMS-907351 (S-malate)
  • A856828
  • (2S)-2-Hydroxybutanedioic acid compd. with N-[4-[(
  • Q27139901
  • trimethyl-(7-methyl-1,4-dihydronaphthalen-1-yl)silane
  • B2693-457054
  • (2S)-2-Hydroxybutanedioic acid compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
  • 1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;(2S)-2-hydroxybutanedioic acid
  • N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-2-hydroxysuccinate
  • Cabozantinib malate, 98%, a potent VEGFR2 inhibitor - 10MG 10mg
  • (2S)-2-Hydroxybutanedioic acid compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluor
  • (2s)-2-hydroxybutanedioic acid compd. with n-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
  • (2S)-2-Hydroxybutanedioic acid compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
  • (2S)-2-Hydroxybutanedioic acid compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
  • (2S)-2-Hydroxybutanedioic acid--N~1~-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'~1~-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (1/1)
  • (2S)-2-hydroxybutanedioic acid; N'1-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
  • 1,1-Cyclopropanedicarboxamide, N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)- mono((2S)-2-hydroxybutanedioate)
  • 114091-64-4
  • 114092-06-7
  • 114092-82-9
  • 114093-21-9
  • 849217-68-1
  • BUTANEDIOIC ACID, 2-HYDROXY-, (2S)-, COMPD. WITH N-(4-((6,7-DIMETHOXY-4-QUINOLINYL)OXY)PHENYL)-N'-(4-FLUOROPHENYL)-1,1-CYCLOPROPANEDICARBOXAMIDE (1:1)
  • Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[4-[(6,7- dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1- cyclopropanedicarboxamide
  • Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1); Cabozantinib S-malate; Cabozantinib s-malate; Cometriq; XL 184; Cabozantinib L-malate salt; Cabozantinib (S)-malate
  • cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide(4-fluoro-phenyl)-amide, (S) malate salt
  • inverted exclamation mark N-[4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl]-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-2-Hydroxysuccinate
  • N'-[4-[(6,7-DIMETHOXY-4-QUINOLINYL)OXY]PHENYL]-N-(4-FLUOROPHENYL)-1,1-CYCLOPROPANEDICARBOXAMIDE
  • N-(4-((6,7-DIMETHOXYQUINOLIN-4-YL)OXY)PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE MONO((2S)-2-HYDROXYBUTANEDIOATE)
  • N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-2-hydroxysuccinate
  • N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (2S)-2-Hydroxybutanedioic Acid
  • N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (2S)-2-hydroxybutanedioate
  • N1-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N1'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;(2S)-2-hydroxybutanedioic acid